Author Archive | Umesh Laddi

Cancer drugs block dementia-linked brain inflammation, study finds

A class of drugs developed to treat immune-related conditions and cancer — including one currently in clinical trials for glioblastoma and other tumors — eliminates neural inflammation associated with dementia-linked diseases and brain injuries, according to UC Irvine researchers. In their study, assistant professor of neurobiology & behavior Kim Green and colleagues discovered that the […]

Continue Reading

FDA Accepts Filing of NDA for IV Antibiotic Oritavancin with Priority Review

FDA Accepts Filing of NDA for IV Antibiotic Oritavancin with Priority Review Oritavancin ( INN, also known as LY333328) is a novel semi-synthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive infections. Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in late 2005. In Dec 2008 the FDA declined to approve […]

Continue Reading

FDA Approves Anoro Ellipta to Treat COPD

A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration. GlaxoSmithKline’s Anoro Ellipta [Combination of  umeclidinium bromide -(see structure-1 left) and vilanterol-structure-2 rightside below) is meant to be used once a day for long-term maintenance of airflow in patients with COPD. […]

Continue Reading

Molecule critical to healing wounds identified

Skin provides a first line of defense against viruses, bacteria and parasites that might otherwise make people ill. When an injury breaks that barrier, a systematic chain of molecular signaling launches to close the wound and re-establish the skin’s layer of protection.  A study led by researchers from the University of Pennsylvania’s School of Dental […]

Continue Reading

FDA Approves Adempas to Treat Pulmonary Hypertension

In continuation of my update on  Adempas (riociguat)…. Food and Drug Administration today approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension… FDA Approves Adempas to Treat Pulmonary Hypertension Medicinal Chemistry Med-Chemist Read Original Post

Continue Reading

New class of antidepressants appears potentially effective in combating deadly form of lung cancer

Jahchan tested the effect of a tricyclic antidepressant called imipramine  (see structure)  on human small-cell lung cancer cells grown in the laboratory and growing as tumors in laboratory mice. She found that the drug was able to potently activate a self-destruction pathway in the cancer cells and to slow or block metastases in the animals. The drug […]

Continue Reading

Cell death protein could offer new anti-inflammatory drug target

Scientists in Melbourne, Australia, have revealed the structure of a protein that is essential for triggering a form of programmed cell death called necroptosis, making possible the development of new drugs to treat chronic inflammatory diseases such as Crohn’s disease and rheumatoid arthritis. Ref :  http://dx.doi.org/10.1016/j.immuni.2013.06.018 Cell death protein could offer new anti-inflammatory drug target […]

Continue Reading